clinical trial · NCT06450236
Bioequivalence Study of Perampanel Tablets 10 mg
Humanis Saglık Anonim Sirketi·phase1·completed·n = 30
EpilepsyPerampanel 10 MGFycompa 10Mg Tablet
brief summary
An open-label, balanced, randomized, two treatment, two sequence, two period, two way cross-over, single dose bioequivalence study of Perampanel Tablets 10 mg of Humanis Sağlık A.ġ., Turkey and Fycompa 10 mg film-coated tablets of Eisai GmbH Edmund-Rumpler-Straße 3 60549 Frankfurt am Main Deutschland in normal, healthy, adult, human subjects under fasting condition.
started
Nov 22, 2023
primary completion
Nov 26, 2023
completion
Feb 6, 2024
last updated
Jun 10, 2024
official title
An Open-label, Balanced, Randomized, Two Treatment, Two Sequence, Two Period, Two Way Cross-over, Single Dose Bioequivalence Study of Perampanel Tablets 10 mg of Humanis Sağlık A.Ş., Turkey and Fycompa 10 mg Film-coated Tablets of Eisai GmbH Edmund-Rumpler-Straße 3 60549 Frankfurt am Main Deutschland in Normal, Healthy, Adult, Human Subjects Under Fasting Condition
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol